Relationship Between Pain Reduction and Improvement in Health-Related Quality of Life in Patients with Knee Pain Due to Osteoarthritis Receiving Duloxetine: Exploratory Post Hoc Analysis of a Japanese Phase 3 Randomized Study
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 13, 181-191
Abstract
Purpose: This post hoc analysis of a Japanese phase 3 randomized study (ClinicalTrials.gov identifier: NCT02248480) investigated relationships between changes in pain severity and changes in health-related quality of life (HRQoL) in duloxetine-treated patients with knee osteoarthritis (OA). Patients and Methods: Patients with knee OA and Brief Pain Inventory (BPI) average pain score ≥ 4 received duloxetine 60 mg/day or placebo for 14 weeks. Spearman rank correlation coefficients were calculated for change in pain severity, as assessed by the BPI, and change in HRQoL, as assessed by the items of the (i) 36-item Short-Form Health Survey (SF-36; a generic measure of HRQoL) and (ii) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; an OA-specific measure of HRQoL). Results: After 14 weeks of treatment, there was a significantly greater improvement (p< 0.001) for duloxetine (n=177) vs placebo (n=176) in BPI average pain severity score and significantly greater improvements (p< 0.01) for duloxetine vs placebo for 5 of the 8 SF-36 domains (including the Role-Physical, Bodily Pain, and Physical Functioning domains) and all 24 individual WOMAC items. The correlation between BPI change from baseline and SF-36 item change from baseline was statistically significant (p< 0.05) for 2 of the 8 SF-36 items (Bodily Pain, Physical Functioning) in duloxetine-treated patients. The correlation between BPI change from baseline and WOMAC item change from baseline was statistically significant for 22 of the 24 WOMAC items in duloxetine-treated patients. Conclusion: This post hoc analysis suggested that the pain reduction observed in duloxetine-treated patients with knee OA was associated with improvements in OA-specific aspects of HRQoL, ie, pain and physical functioning.Keywords
This publication has 28 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritisJournal of Pain Research, 2018
- Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studiesScientific Reports, 2016
- Placebo analgesia: understanding the mechanismsPain Management, 2015
- Reward and motivation in pain and pain reliefNature Neuroscience, 2014
- The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional studyBMJ Open, 2013
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the KneePain Practice, 2011
- Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trialPain, 2009
- VALIDATION-STUDY OF WOMAC - A HEALTH-STATUS INSTRUMENT FOR MEASURING CLINICALLY IMPORTANT PATIENT RELEVANT OUTCOMES TO ANTIRHEUMATIC DRUG-THERAPY IN PATIENTS WITH OSTEO-ARTHRITIS OF THE HIP OR KNEE1988
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986